CTOs on the Move

Paradigm Capital

www.paradigmcapinc.com

 
Paradigm Capital Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Our Lady of the Valley Retirement Community

Our Lady of the Valley is a non-profit, non-denominational senior living community that provides assisted living, long term nursing, and skilled rehabilitation care. They strive to enhance the quality of life for their senior living residents through p...

WesleyLife

Simply put, we`re transforming the aging experience so people live longer, healthier lives. By focusing on each person`s abilities and strengths–rather than their limitations–we believe we can impact the healthspan of older adults. Ignited by a passion to inspire older adults to live healthy, meaningful lives, we reach out with our ministries which include: independent and assisted living, rehabilitation, memory support and services including home care, adult day, home-delivered meals, hospice and transportation. As a nonprofit organization guided by Christian compassion, we were founded than 66 years ago as a place for aging Methodist ministers and their spouses to call home. Today, our services are delivered by 1,300 part- and full-time passionate team members throughout the state with a focus on creating healthier and longer lives.

Magpie Healthcare

Magpie Healthcare is a Denver, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PeriGen, Inc.

PeriGen, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Enterin Inc.

Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.